13 July 2022>: Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak 1ACDEF* , Marcin Mazurek 1BCEF , Aleksandra Majdan 1DEF , Radosław Mlak 1ACDE , Maria Majdan 2ADEF , Teresa Mełecka-Massalska 1ADEFDOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 2 Differences in calprotectin value depending on demographic and clinical factors in the study group.
Variable | Median | p |
---|---|---|
Male | 3.10 | 0.7735 |
Female | 3.11 | |
Age (years) | 0.0562 | |
3.14 | ||
>36.5 | 3.06 | |
Duration of the disease (years) | 0.8611 | |
3.11 | ||
>6 | 3.10 | |
SLEDAI | 0.6907 | |
Mild and moderate | 3.11 | |
Severe | 3.41 | |
SLEDAI | 0.2030 | |
Mild | 3.11 | |
Moderate and severe | 3.39 | |
Calprotectin [ng/ml] | 0.0013* | |
Study group | 3.11 | |
Control group | 2.45 | |
* Statistically significant results. SLEDAI – Systemic Lupus Erythematosus Disease Activity Index. |